drugset / Trial / NCT01457144
Study of Mantle Cell Lymphoma Treatment by RiBVD
Phase 2
Completed
76 enrolled
French Innovative Leukemia Organisation
Chugai Pharma Europe Ltd. · collabJanssen-Cilag Ltd. · collabLymphoma Study Association · collabMundipharma Pte Ltd. · collabRoche Pharma AG · collab
NaSingle-groupOpen-labelTreatment
Summary
Study of First line mantle cell lymphoma treatment by Rituximab, Velcade, Bendamustine and Dexamethasone schema in patients older than 65 years or 18 to 65 years old who cannot or refuse receive conditioning regimen followed by autograft.
Timeline
- Start
- 2011-10
- Primary completion
- 2014-09
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 90 mg/m2 | Other |
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Subject | Dexamethasone | Small molecule | 40 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |